Fosun International Ltd Holds Position in Check-Cap Ltd. (CHEK)

Fosun International Ltd held its position in Check-Cap Ltd. (NASDAQ:CHEK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,530,699 shares of the medical research company’s stock at the end of the 2nd quarter. Check-Cap makes up about 0.4% of Fosun International Ltd’s portfolio, making the stock its 26th largest position. Fosun International Ltd owned 9.79% of Check-Cap worth $2,954,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Knott David M grew its holdings in Check-Cap by 1.9% in the 1st quarter. Knott David M now owns 162,871 shares of the medical research company’s stock valued at $349,000 after buying an additional 3,000 shares during the last quarter. 19.29% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/09/17/fosun-international-ltd-holds-position-in-check-cap-ltd-chek.html.

A number of analysts have issued reports on CHEK shares. Zacks Investment Research lowered Check-Cap from a “buy” rating to a “hold” rating in a report on Friday, June 16th. ValuEngine lowered Check-Cap from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright set a $6.00 target price on Check-Cap and gave the company a “buy” rating in a report on Friday, August 11th. Finally, Maxim Group reaffirmed a “buy” rating on shares of Check-Cap in a report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Check-Cap currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Shares of Check-Cap Ltd. (NASDAQ:CHEK) traded down 3.28% during mid-day trading on Friday, hitting $1.77. The stock had a trading volume of 4,767 shares. Check-Cap Ltd. has a 52 week low of $1.70 and a 52 week high of $2.95. The stock has a 50 day moving average of $1.78 and a 200-day moving average of $1.95. The stock’s market capitalization is $30.05 million.

Check-Cap (NASDAQ:CHEK) last announced its earnings results on Thursday, August 10th. The medical research company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). On average, equities research analysts predict that Check-Cap Ltd. will post ($0.63) earnings per share for the current year.

Check-Cap Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Institutional Ownership by Quarter for Check-Cap (NASDAQ:CHEK)

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply